Researchers examined the genetic variants associated with the transition from hyperuricemia to gout.
Researchers studied subclinical inflammation in intercritical gout and its association with the size of monosodium urate crystal deposition and cardiovascular risk factors.
Robert T. Keenan, MD, discusses the role of co-treatment with immunomodulators and pegloticase in patients with uncontrolled gout.
Researchers studied metabolic alterations and dysregulated metabolic pathways in hyperuricemia and gout, and discovered potential metabolite biomarkers to differentiate between gout and asymptomatic hyperuricemia.
Researchers tested the hypothesis that the association of traits representing hyperuricemia and its comorbidities is genetically based.
Researchers evaluated the effect of mycophenolate mofetil on the efficacy of pegloticase in patients with refractory gout.
New study is the first to characterize pegloticase use in the dialysis population.
Annual volume of cardiac procedures for patients with gout exceeded those for patients with RA from 1998 to 2014
Patient characteristics, such as dialysis use and diabetes status, appeared to be influential factors.
Study authors examined the accuracy of dual-energy computed tomography vs ultrasound, or their combination, for the diagnosis of gout.